BI-836826
- Generic Name
- BI-836826
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- LB090AB8DB
- Associated Conditions
- -
- Associated Therapies
- -
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT03343678
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7
- Registration Number
- NCT02759016
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Oregon Health and Sciences University, Portland, Oregon, United States
🇺🇸City of Hope, Duarte, California, United States
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL
- Conditions
- Interventions
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT02624492
- Locations
- 🇪🇸
Hospital La Paz, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Spain
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 2
- Registration Number
- NCT02538614
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT01403948
- Locations
- 🇫🇷
HOP Lyon Sud, Pierre Bénite, France
🇩🇪Asklepios Klinik St. Georg, Hamburg, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT01296932
- Locations
- 🇧🇪
UNIV UZ Gent, Gent, Belgium
🇫🇷CTR Investigation Clinique, onco, Montpellier, Montpellier Cedex 5, France
🇫🇷INS Universitaire du Cancer, Toulouse, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.